OVERVIEW

Baylor Annette C. and Harold C. Simmons Transplant Institute in conjunction with the Camenae Group invite you to join them for the mTOR in Liver Transplantation: Fact and Fiction Symposium on Saturday, March 28, 2015, at the Grand Hyatt in Terminal D of D/FW International Airport. This activity is designed for physicians treating solid organ transplant recipients with mTOR inhibitors.

mTOR inhibitors and liver transplantation have had a complicated relationship. Few medications in liver transplantation evoke such strong opinions - they are either loved or loathed by clinicians. An FDA black box warning on de novo use, based on results of the early registration trials, has limited the widespread adoption of mTOR inhibitors. Despite the warning, many clinicians have continued to use these drugs because of their perceived advantages, particularly some of the beneficial side effects that can occur with inhibition of the multifaceted mTOR cellular pathway.

Researchers and clinicians will present cases and initiate conversations with the audience in order to achieve the overall goal of the activity:

- Evaluate the safety and efficacy of mTOR inhibitors in liver transplantation.
- Consider the future applications of mTOR inhibitors in liver transplantation.
- Evaluate the side effects and benefits of mTOR inhibitors in solid organ transplant recipients.

Whatever your opinion, whatever you have heard, or whatever you think you know, this ground-breaking symposium will help shape the future role of mTOR inhibitors in liver transplantation. Leading researchers and liver transplant clinicians will debate their use and report on their experiences and outcomes. This is your chance - be part of that conversation. Be part of that debate.

PROGRAM CHAIRS

John R. Lake, MD
Chief of Hepatology
Director, Liver Transplant Program
University of Minnesota Medical School • Duluth, Minnesota

James Trotter, MD
Director, General and Transplant Hepatology
Baylor University Medical Center • Dallas, Texas

FACULTY

GJM Alexander, MD
Consultant Hepatologist, Cambridge Hepatobiliary Service
Addenbrooke’s Hospital • Cambridge, UK

Michael Charlton, MD
Professor of Medicine
Intermountain Medical Center • Salt Lake City, Utah
Eric Engels, MD
Senior Investigator, National Cancer Institute at NIH
Rockville, Maryland

John Fung, MD, PhD
Chairman, Department of Surgery
Director, Transplant Center
Cleveland Clinic • Cleveland, Ohio

Edward Geissler, MD
Director of Experimental Surgery
University Hospital Regensburg • Regensburg, Germany

Igal Kam, MD
Professor of Surgery
Univ. of Colorado School of Medicine • Denver, Colorado

Goran Klintmalm, MD, PhD
Chairman and Chief
Annette C. and Harold C. Simmons Transplant Institute • Dallas, Texas

Norman Kneteman, MD
Professor of Surgery
Director, Division of Transplantation
University of Alberta Hospital • Edmonton, Canada

Josh Levitsky, MD
Director, Liver Transplant
Northwestern Memorial Hospital • Chicago, Illinois

Greg McKenna, MD
Director, Transplant Surgery Research
Baylor University Medical Center • Dallas, Texas

Randy Morris, MD
Research Professor (Emeritus) of Cardiothoracic Surgery
Stanford University School of Medicine • Stanford, California

Russell Wiesner, MD
Professor of Medicine
Mayo Clinic College of Medicine • Rochester, Minnesota

DEBATE PARTICIPANTS

Charles Miller, MD
Abraham Shaked, MD, PhD
Robert Brown, MD, PhD
Mark Ghobrial, MD, PhD
Michael Abecassis, MD
Timothy Pruett, MD
James Eason, MD
Elizabeth Pomfret, MD, PhD
Lewis Teperman, MD

AGENDA
SESSION 1
7:00a  Group Breakfast
8:00  Overview of the Development of Sirolimus and Everolimus in Liver Transplantation
      John R. Lake, MD
8:10  Overview of the Diverse Biologic Properties of mTOR Inhibitors
      Randy Morris, MD
8:30  De Novo Trials of Sirolimus in Liver Transplantation
      Russell Wiesner, MD (8:30)
      John J. Fung, MD, PhD (8:50)
9:10  Discussion
9:30  Break

SESSION 2
10:00 Conversion Trials of Everolimus and Sirolimus for Renal-Sparing
      James Trotter, MD
10:20 Single-center Experiences with mTOR Inhibitors
      Norman Kneteman, MD (10:20)
      Igal Kam, MD (10:35)
      Göran Klintmalm, MD, PhD (10:50)
11:05 There is No Evidence Sirolimus Has Any Beneficial Effect for Any Indication in Liver Transplantation
      Michael R. Charlton, MD
11:25  Discussion

SESSION 3
12:00 p  Group Lunch
1:00  mTOR Inhibitors in the Treatment and Prevention of Hepatocellular Carcinoma, The Silver Study
      Edward Geissler, MD
1:20  mTOR Inhibitors in the Treatment and Prevention of Non-Hepatoma Malignancies
      Eric Engels, MD
1:40  Side Effects - Facts and Fiction
      Greg McKenna, MD
2:00  Discussion
2:20  Break

SESSION 4
3:00  Sirolimus vs. Everolimus: Is There a Difference?
      GJM Alexander, MD
3:15  Tolerance Development and mTOR
      Josh Levitsky, MD
3:30  The Way Forward
      John R. Lake, MD
3:40  Discussion
4:00  Evaluations / ADJOURN
5:00  White Paper Draft
      Presenters and Organizers

VENUE / ACCOMMODATIONS
Grand Hyatt - D/FW Airport, Terminal D
2337 South International Parkway
D/FW Airport, TX 75261
Tel: 972.973.1234 • Web: www.granddfw.hyatt.com
A room block has been established at the Grand Hyatt for Symposium attendees.